Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System

Guillermo Tarrasó, Miriam Umbria, Noelia Paco, Roser Vives, Montserrat Gasol, Antonio Vallano

Open source

DOI: 10.1007/s40801-026-00585-3
Published: 2026-11-03
Container: Drugs - Real World Outcomes
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40801-026-00585-3,
  title = {Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System},
  author = {Guillermo Tarrasó and Miriam Umbria and Noelia Paco and Roser Vives and Montserrat Gasol and Antonio Vallano},
  year = {2026},
  journal = {Drugs - Real World Outcomes},
  doi = {10.1007/s40801-026-00585-3},
  url = {https://doi.org/10.1007/s40801-026-00585-3}
}

RIS

TY  - JOUR
TI  - Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System
AU  - Guillermo Tarrasó
AU  - Miriam Umbria
AU  - Noelia Paco
AU  - Roser Vives
AU  - Montserrat Gasol
AU  - Antonio Vallano
PY  - 2026
JO  - Drugs - Real World Outcomes
DO  - 10.1007/s40801-026-00585-3
UR  - https://doi.org/10.1007/s40801-026-00585-3
ER  -

APA

Tarrasó, G., Umbria, M., Paco, N., Vives, R., Gasol, M., & Vallano, A. (2026). Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System. Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-026-00585-3

Source records

crossref · retrieved 2026-11-08T00:21:05.191Z